Clinical Trials

Phase 4 Active not recruiting

Breast Neoplasms, Breast Neoplasms, Male

NCT05161195 2026-02-02

Roll-over Study to Allow Continued Access to Ribociclib

134 enrolled

Breast Neoplasms

NCT03056755 2026-01-13

BYLieve

383 enrolled 16 charts

Breast Neoplasms, Hereditary Sensory and Autonomic Neuropathies

NCT03671330 2025-10-31

Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.

327 enrolled

Breast Neoplasms

NCT05607004 2025-10-30

EVANGELINE

Phase 2 Recruiting

87 enrolled

Breast Neoplasms

NCT03822468 2025-10-16

AMALEE

376 enrolled 17 charts

Breast Neoplasms

NCT04478266 2025-09-11

AMEERA-5

Phase 3 Terminated

1,068 enrolled 21 charts

Breast Neoplasms

NCT05870579 2025-08-21

[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer

Phase 1 Recruiting

48 enrolled

Breast Neoplasms

NCT03936933 2025-02-17

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

Phase 3 Terminated

6 enrolled

Breast Neoplasms

NCT03839823 2024-10-09

RIGHT Choice

222 enrolled 17 charts

Breast Neoplasms

NCT04862143 2024-06-20

TELEPIK

Phase 2 Terminated

2 enrolled 10 charts

Advanced Breast Cancer

NCT03272477 2024-04-17

TP-II

257 enrolled

Breast Neoplasms

NCT02278120 2024-03-12

MONALEESA-7

672 enrolled 16 charts 1 FDA

Advanced Metastatic Breast Cancer

NCT02941926 2023-10-24

COMPLEEMENT-1

3,246 enrolled 11 charts

Breast Neoplasms

NCT02333370 2023-06-08

A Phase Ib Dose Escalation Study of the Combination of LEE011 With Letrozole and Dose Expansion of LEE011 With Hormonal Therapy for the Treatment of Pre-(With Goserelin) and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

Phase 1 Completed

88 enrolled

Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer

NCT05110170 2023-05-16

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

188 enrolled

Breast Neoplasms

NCT03096847 2021-10-11

Study for Women and Men With Hormone-receptor Positive Locally Advanced or Metastatic Breast Cancer

502 enrolled 20 charts

Breast Neoplasms, Osteitis Deformans

NCT03658213 2021-05-10

LARES

Phase 3 Withdrawn

Breast Neoplasms

NCT01073865 2018-12-12

Study to Compare Zoladex™ 10.8 mg With Zoladex 3.6 mg in Pre-menopausal Women With Breast Cancer

222 enrolled 13 charts

Breast Neoplasms

NCT00605267 2012-09-06

Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment

197 enrolled 23 charts

Breast Neoplasms, Neoplasms

NCT00322348 2011-01-24

Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women

98 enrolled 13 charts

Breast Neoplasms, Neoplasms

NCT00235937 2011-01-21

Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex

45 enrolled

Breast Neoplasms

NCT00888082 2010-12-10

PROOF

Phase 3 Withdrawn

102 enrolled

Breast Neoplasms

NCT00303524 2009-12-23

Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients

170 enrolled